Alkermes Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Blair Jackson
Chief executive officer
US$4.0m
Total compensation
| CEO salary percentage | 18.27% |
| CEO tenure | no data |
| CEO ownership | 0.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$66m |
| Mar 31 2026 | n/a | n/a | US$153m |
| Dec 31 2025 | US$4m | US$736k | US$242m |
| Sep 30 2025 | n/a | n/a | US$338m |
| Jun 30 2025 | n/a | n/a | US$348m |
| Mar 31 2025 | n/a | n/a | US$356m |
| Dec 31 2024 | US$5m | US$715k | US$372m |
| Sep 30 2024 | n/a | n/a | US$387m |
| Jun 30 2024 | n/a | n/a | US$386m |
| Mar 31 2024 | n/a | n/a | US$570m |
| Dec 31 2023 | US$5m | US$650k | US$519m |
| Sep 30 2023 | n/a | n/a | US$455m |
| Jun 30 2023 | n/a | n/a | US$300m |
| Mar 31 2023 | n/a | n/a | -US$9m |
| Dec 31 2022 | US$4m | US$600k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$129m |
| Jun 30 2022 | n/a | n/a | -US$94m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$4m | US$540k | US$76m |
Compensation vs Market: Blair's total compensation ($USD4.03M) is above average for companies of similar size in the German market ($USD2.77M).
Compensation vs Earnings: Blair's compensation has been consistent with company performance over the past year.
CEO
Blair Jackson (53 yo)
Mr. Blair C. Jackson is CEO & Director of Alkermes plc from August 1, 2026. Mr. Jackson is Director of Synchronicity Pharma, Inc. (formerly known as Reset Therapeutics, Inc.) since May 11, 2016. Mr. Jackso...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$4.03m | 0.14% € 10.3m | |
| Senior VP & CFO | less than a year | US$4.23m | no data | |
| Executive VP | 10.3yrs | US$3.47m | 0.13% € 9.6m | |
| Executive VP of Research & Development and Chief Medical Officer | 9.3yrs | US$3.62m | 0.041% € 3.0m | |
| Senior VP & Chief Commercial Officer | 6.3yrs | US$2.79m | 0.065% € 4.7m | |
| Interim Principal Accounting Officer & VP of Finance | 2.5yrs | no data | 0.0046% € 328.8k | |
| SVP & Chief Information Officer | less than a year | no data | no data | |
| Senior Vice President of Corporate Affairs & Investor Relations | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | 6.2yrs | no data | no data | |
| SVP of Policy | no data | no data | no data | |
| Senior Vice President of Operations and Environment | no data | no data | no data | |
| Senior Vice President of Quality | no data | no data | no data |
Experienced Management: 8AK's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$4.03m | 0.14% € 10.3m | |
| Chairman | 14.9yrs | US$7.92m | 0.82% € 58.7m | |
| Independent Director | 5.7yrs | US$491.33k | 0.029% € 2.1m | |
| Independent Director | 10.3yrs | US$479.14k | 0.022% € 1.5m | |
| Independent Director | 2.4yrs | US$476.21k | 0.011% € 776.1k | |
| Independent Director | 8.4yrs | US$484.75k | 0.064% € 4.5m | |
| Independent Director | 4.8yrs | US$461.01k | 0.020% € 1.4m | |
| Lead Independent Director | 6.9yrs | US$527.23k | 0.021% € 1.5m | |
| Independent Director | 4.3yrs | US$477.84k | 0.015% € 1.1m | |
| Independent Director | 6.9yrs | US$474.01k | 0.021% € 1.5m |
Experienced Board: 8AK's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/10 05:42 |
| End of Day Share Price | 2026/08/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkermes plc is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Luke Herrmann | Baird |